FTC v. Shire ViroPharma Inc

Track this case

Case Number:

18-1807

Court:

Appellate - 3rd Circuit

Nature of Suit:

1410 Antitrust

Companies

Government Agencies

Sectors & Industries:

  1. February 25, 2019

    FTC Can't Challenge Past Conduct In Court, 3rd Circ. Says

    A Third Circuit panel on Monday rejected the Federal Trade Commission's bid to revive its suit accusing a Shire PLC unit of delaying generic competition for a gastrointestinal infection drug several years ago through sham regulatory filings, saying the agency can't challenge purely past conduct in federal courts.

  2. January 01, 2019

    Life Sciences Cases To Watch In 2019

    The life sciences industry will be keeping an eye on courtrooms around the country in 2019, watching to see how the U.S. Supreme Court decides a legal battle over patent protection for drugs and monitoring the fallout from federal prosecutors' decision to spike a False Claims Act case. Here are seven cases life sciences attorneys say they'll be following in the coming year.

  3. December 11, 2018

    3rd Circ. Questions 'Imminent' Shire Antitrust Actions

    The Third Circuit pressed the Federal Trade Commission on Tuesday to show why the court should revive the agency's antitrust complaint alleging a Shire PLC unit delayed generic competition for a gastrointestinal infection drug through a series of sham regulatory petitions, expressing skepticism that a violation of federal law was "imminent."

  4. October 17, 2018

    FTC On Ropes As Courts Wallop Suits Over Past Conduct

    The Federal Trade Commission's power to punish past conduct involving consumer fraud or anti-competitive shenanigans is looking wobbly after a one-two punch of court decisions forcing the agency to also identify imminent or ongoing violations when it challenges prior behavior.

  5. August 31, 2018

    Pharma Cases To Watch In 2018's Home Stretch

    Drugmakers in the closing months of 2018 may see pivotal rulings on novel efforts to hamstring rival medicines, escalating drama in multidistrict litigation over the opioid epidemic, and opening salvos in False Claims Act and drug-pricing fights at the U.S. Supreme Court. Here, Law360 summarizes key cases to watch.

  6. August 13, 2018

    FTC Overstepped In Shire FDA Petitions Case, 3rd Circ. Told

    The Federal Trade Commission exceeded its authority in bringing a lawsuit that alleges a Shire PLC unit abused the U.S. Food and Drug Administration's citizen petition process to delay generic competition for its antibiotic Vancocin and is overstating potential consequences of the lower court's dismissal, the Washington Legal Foundation has told the Third Circuit.

  7. August 03, 2018

    ​​​​​​​FTC Can't Block Theoretical Drugmaker Moves, Shire Says

    The Federal Trade Commission is exceeding its authority by trying to preemptively block Shire ViroPharma Inc. from petitioning the U.S. Food and Drug Administration to delay generic competition based on theoretical concerns it may do so, the drugmaker told the Third Circuit in a newly filed brief.